Checkmate Pharmaceuticals, Inc.

Checkmate Pharmaceuticals, Inc. is a clinical stage biotechnology company focused on developing its proprietary technology to harness the power of the immune system to combat cancer. The Company's product candidate, vidutolimod (CMP-001), is an advanced generation Toll-like receptor 9 (TLR9) agonist, delivered as a biologic virus-like particle (VLP) utilizing a CpG-A oligodeoxynucleotide as a key component, designed to trigger the body's innate immune system to attack tumors in combination with other therapies. The Company is conducting a Phase II trial of vidutolimod in combination with nivolumab (OPDIVO), in anti-PD-1 refractory melanoma. The Company is also conducting a randomized Phase II/III trial of vidutolimod in combination with nivolumab in first-line melanoma. The Company's VLP technology is designed to encapsulate and protect the CpG-A oligonucleotide from degradation in the tumor.